Aug 17, 2023 / 06:30PM GMT
Arthur He - HC Wainwright & Co., LLC - Analyst
Greetings. My name is Arthur He, a senior biotech analyst at HC Wainwright. And thanks for joining us to have a conversation with BioAtla's management: Ms. Sheri Lydick, Chief Commercial Officer; Dr. Eric Sievers, Chief Medical Officer; and Dr. William Boyle, Head of Translational Science.
BioAtla is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinical development and multiple preclinical candidates across different modalities. Today's conversation will be focused on their bispecific T-cell engagers.
To discuss the company's CAB technology and its development strategy in T-cell engagers, I welcome Sheri, Eric, and Bill to this fireside chat. Good day, Sheri, Eric, and Bill.
William Boyle - BioAtla, Inc. - Senior Research Fellow
Welcome. Thank you.
Sheri Lydick - BioAtla, Inc. - Chief Commercial Officer
Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript
Aug 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers